Sulbactam-durlobactam: A Step Forward in Treating Carbapenem-Resistant Acinetobacter baumannii (CRAB) Infections

被引：8

作者：

Watkins, Richard R. ^{[1
,4
]}

Bonomo, Robert A. ^{[2
,3
]}

机构：

[1] Northeast Ohio Med Univ, Dept Med, Div Infect Dis, Rootstown, OH USA

[2] VA Northeast Ohio Healthcare Syst, Res Serv, Cleveland, OH USA

[3] Case Western Reserve Univ, Cleveland VA Med Ctr Antimicrobial Resistance & Ep, Cleveland, OH USA

[4] Northeast Ohio Med Univ, Dept Med, 4209 St,OH 44, Rootstown, OH 44272 USA

来源：

CLINICAL INFECTIOUS DISEASES | 2023年 / 76卷

关键词：

antimicrobial resistance; carbapenem-resistant Acinetobacter baumannii; sulbactam-durlobactam; BETA-LACTAM ANTIBIOTICS;

D O I：

10.1093/cid/ciad093

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Antimicrobial resistance in gram-negative pathogens, such as Acinetobacter baumannii, is a serious threat to human health. Sulbactam-durlobactam, a unique beta-lactam and a beta-lactamase inhibitor combination, is a novel agent targeted against carbapenem-resistant A. baumannii. This supplement provides a summary of the development of SUL-DUR, discussing its unique features and role in treating infections caused by CRAB pathogens.

引用

页码：S163 / S165

页数：3

共 50 条

[41] Global spread of carbapenem-resistant Acinetobacter baumannii
Higgins, Paul G.
Dammhayn, Cathrin
Hackel, Meredith
Seifert, Harald
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2010, 65 (02) : 233 - 238
[42] A global view on carbapenem-resistant Acinetobacter baumannii
Mueller, Carina
Reuter, Sandra
Wille, Julia
Xanthopoulou, Kyriaki
Stefanik, Danuta
Grundmann, Hajo
Higgins, Paul G.
Seifert, Harald
MBIO, 2023, 14 (06)
[43] Semimechanistic Pharmacokinetic/Pharmacodynamic Modeling of Fosfomycin and Sulbactam Combination against Carbapenem-Resistant Acinetobacter baumannii
Lim, Sazlyna Mohd Sazlly
Heffernan, Aaron J.
Roberts, Jason A.
Sime, Fekade B.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2021, 65 (05)
[44] Risk factors for carbapenem-resistant Acinetobacter baumannii (CRAB) bloodstream infections and related mortality in critically ill patients with CRAB colonization
Cogliati Dezza, Francesco
Covino, Sara
Petrucci, Flavia
Sacco, Federica
Viscido, Agnese
Gavaruzzi, Francesca
Ceccarelli, Giancarlo
Raponi, Gianmarco
Borrazzo, Cristian
Alessandri, Francesco
Mastroianni, Claudio Maria
Venditti, Mario
Oliva, Alessandra
JAC-ANTIMICROBIAL RESISTANCE, 2023, 5 (04):
[45] Comparison of Tigecycline or Cefoperazone/Sulbactam therapy for bloodstream infection due to Carbapenem-resistant Acinetobacter baumannii
Niu, Tianshui
Luo, Qixia
Li, Yaqing
Zhou, Yanzi
Yu, Wei
Xiao, Yonghong
ANTIMICROBIAL RESISTANCE AND INFECTION CONTROL, 2019, 8 (1)
[46] Associations between Carbapenem Use, Carbapenem-Resistant Pseudomonas aeruginosa, and Carbapenem-Resistant Acinetobacter baumannii
Apisarnthanarak, Anucha
Jitpokasem, Sumana
Mundy, Linda M.
INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY, 2013, 34 (11): : 1235 - 1237
[47] Comparison of Tigecycline or Cefoperazone/Sulbactam therapy for bloodstream infection due to Carbapenem-resistant Acinetobacter baumannii
Tianshui Niu
Qixia Luo
Yaqing Li
Yanzi Zhou
Wei Yu
Yonghong Xiao
Antimicrobial Resistance & Infection Control, 8
[48] Treatment Options for Carbapenem-Resistant and Extensively Drug-Resistant Acinetobacter baumannii Infections
Viehman, J. Alexander
Hong Nguyen, M.
Doi, Yohei
DRUGS, 2014, 74 (12) : 1315 - 1333
[49] Bibliometric Examination of Global Scientific Research about Carbapenem-Resistant Acinetobacter Baumannii (CRAB)
Jangid, Himanshu
Kumar, Deepak
Kumar, Gaurav
Kumar, Raj
Mamidi, Narsimha
ANTIBIOTICS-BASEL, 2023, 12 (11):
[50] Adaptive resistance to cefiderocol in carbapenem-resistant Acinetobacter baumannii (CRAB): microbiological and clinical issues
Desmoulin, Anissa
Sababadichetty, Loik
Kamus, Laure
Daniel, Marion
Feletti, Lucie
Allou, Nicolas
Potron, Anals
Leroy, Anne-Gaelle
Jaffar-Bandjee, Marie -Christine
Belmonte, Olivier
Garrigos, Thomas
Miltgen, Guillaume
HELIYON, 2024, 10 (09)

← 1 2 3 4 5 →